Skip to main content

Table 1 Autoantibodies and other laboratory parameters in SLE patients at randomization

From: Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective, randomized, double-masked, placebo-controlled study

 

Range (mean ± SD)

Number (%) of patients with out-of-range values

ANA (titer)

0-1/20480

56 (93.3%)

C3c (g/l)

0.43-1.39 (0.90 ± 0.25)

32 (53.3%)

C4 (g/l)

0.02-0.26 (0.13 ± 0.05)

16 (26.7%)

LA

-

11 (18.3%)

aCL IgG (RU/ml)

0.68-121.56 (14.4 ± 20.3)

20 (33.3%)

aCL IgM (RU/ml)

1.62-52.93 (12.1 ± 10.6)

26 (43.3%)

antiβ2GPI IgG (RU/ml)

0.16-95.33 (3.8 ± 15.3)

8 (13.3%)

antiβ2GPI IgM (RU/ml)

0.14-21.66 (2.2 ± 3.7)

24 (40%)

  1. aCL, anticardiolipin antibodies; ANA, antinuclear antibodies; antiβ2GPI, antiβ2-glycoprotein I antibodies; LA, lupus anticoagulant; SD, standard deviation; SLE, systemic lupus erythematosus.
  2. Abnormal low levels for C3c: < 0.9 g/l, for C4: < 0.1 g/l. Cut-off value for aCL IgG: > 20 RU/ml, aCL IgM: > 30 RU/ml, antiβ2GPI IgG: > 3 RU/ml, antiβ2GPI IgM > 2.6 RU/ml.